Cencora Inc. Q3 2026 Earnings Recap

COR Q3 2026 August 7, 2026

Get alerts when COR reports next quarter

Cencora’s stock rose 6.1% following the Q3 report, driven by double-digit adjusted operating income growth and a raised fiscal 2026 EPS guidance, signaling investor approval of the company's execution and strategic positioning in specialty pharmaceuticals.

Earnings Per Share Beat

$4.48 vs $4.35 est.

+3.0% surprise

Revenue Beat

84754840000 vs 84314550000 est.

+0.5% surprise

Market Reaction

1-Day +1.42%

5-Day -2.07%

See COR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted operating income grew double digits in Q3, underpinning profitability momentum.
Executed $1 billion in opportunistic share repurchases, supporting a 12% increase in EPS for the quarter.
Raised fiscal 2026 EPS guidance, reflecting management’s confidence in continued operational execution and portfolio strength.
Specialty pharmaceutical platform advances and digital transformation initiatives, including AI-driven demand forecasting, highlight strategic focus areas.
New CFO and CHRO appointments signal strengthened leadership continuity and commitment to talent development.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit COR on AllInvestView.

Previous Q2 2026